Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type I or Type II HAE.~* History of angioedema attacks.~Exclusion Criteria:~* History of bleeding or clotting abnormality.~* Diagnosis of acquired angioedema or known to have C1 INH antibodies.~* History of allergic reaction to C1 esterase inhibitor or other blood products.~* Receipt of any experimental agents other than those required for prevention or treatment of angioedema attacks within 30 days prior to screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 500/1000 (Type: EXPERIMENTAL): 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
- 1000/500 (Type: EXPERIMENTAL): 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).